Component

Apigenin

Context-specific entity; species, compartment and exposure are stated on each claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

Where it participates (unsigned role)

  1. Recombinant human CYP1A2 supported apigenin 3′-hydroxylation to luteolin.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Human CYP expression and liver microsomes.
    limitations
    Not evidence that the two oral products give equivalent exposures.
    nutrient_topic
    Luteolin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Luteolin / 3′,4′,5,7-tetrahydroxyflavone
    plain_language
    A related flavone can be converted into luteolin.
    primary_references
    In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. · 2002 · https://pubmed.ncbi.nlm.nih.gov/11955666/ · DOI 10.1016/s0278-6915(01)00125-9

    Luteolin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 140–146

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Human CYP expression and liver microsomes. · source_derived_draft · unverified_draft

    ## luteolin-cyp1a2-apigenin A related flavone can be converted into luteolin. Recombinant human CYP1A2 supported apigenin 3′-hydroxylation to luteolin. Model: Human CYP expression and liver microsomes. Limitations: Not evidence that the two oral products give equivalent exposures. Evidence access: Primary abstract In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. · 2002 · https://pubmed.ncbi.nlm.nih.gov/11955666/ · DOI 10.1016/s0278-6915(01)00125-9
    Complete structured claim and evidence
  2. Recombinant human CYP3A4 supported apigenin 3′-hydroxylation to luteolin.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Human CYP expression and liver microsomes.
    limitations
    Not evidence that the two oral products give equivalent exposures.
    nutrient_topic
    Luteolin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Luteolin / 3′,4′,5,7-tetrahydroxyflavone
    plain_language
    A related flavone can be converted into luteolin.
    primary_references
    In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. · 2002 · https://pubmed.ncbi.nlm.nih.gov/11955666/ · DOI 10.1016/s0278-6915(01)00125-9

    Luteolin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 148–154

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Human CYP expression and liver microsomes. · source_derived_draft · unverified_draft

    ## luteolin-cyp3a4-apigenin A related flavone can be converted into luteolin. Recombinant human CYP3A4 supported apigenin 3′-hydroxylation to luteolin. Model: Human CYP expression and liver microsomes. Limitations: Not evidence that the two oral products give equivalent exposures. Evidence access: Primary abstract In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. · 2002 · https://pubmed.ncbi.nlm.nih.gov/11955666/ · DOI 10.1016/s0278-6915(01)00125-9
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards